Metformin in patients with chronic kidney disease: strengths and weaknesses
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A wide array of benefits has been attributed to metformin. These include attenuation of abnormal glucose metabolism (diabetes treatment and prevention), weight neutrality or weight loss, improvement in the pathophysiologic components of metabolic syndrome (insulin resistance, subclinical inflammation, and endothelial dysfunction), lipid-lowering properties, cardiovascular protection, and antineoplastic potential. Metformin itself is not a nephrotoxic drug. Initially appointed as the safest hypoglycemic agent in chronic kidney disease, its use has been limited in these patients because of the perceived risk of lactic acidosis. A fear perpetuated by numerous case reports in which it is implicated. Current guidelines stipulate that it must be used with caution in estimated glomerular filtration rates (eGFRs) of less than 60 mL/minute and not at all in eGFRs of less than 30 mL/minute. Identified risk factors for metformin-associated lactic acidosis include acute kidney injury, hypoxemia, sepsis, alcohol abuse, liver failure, myocardial infarction, and shock. Treatment may include supportive care and dialysis techniques. On the other hand, it is likely that the use of metformin would be beneficial in many with chronic kidney disease according to the advantages associated with attenuation of metabolic syndrome and cardiovascular protection. The reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment raises the question of limitation of its use in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani, A. A., Varughese, G. I., Scarpello, J. H., & Hanna, F. W. F. (2007) · BMJ · doi:10.1136/bmj.39255.669444.ae · Cited by 138
Frid, A., Sterner, G. N., Löndahl, M., Wiklander, C., Cato, A., Vinge, E., & Andersson, A. (2010) · Diabetes Care · doi:10.2337/dc09-1284 · Cited by 126
Impact of treating the metabolic syndrome on chronic kidney disease
Agrawal, V., Shah, A., Rice, C., Franklin, B. A., & McCullough, P. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.114 · Cited by 62
Prolonged Hemodialysis for Severe Metformin Intoxication
Rifkin, S. I., McFarren, C., Juvvadi, R., & Weinstein, S. S. (2011) · Renal Failure · doi:10.3109/0886022x.2011.568132 · Cited by 26
Cited by
Metformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658
“[10] Rocha A, Almeida M, Santos J, Carvalho A.”
BackgroundPharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft536 · Cited by 89
Metadata
- Authors
- Rocha, A., Almeida, M., Santos, J., & Carvalho, A.
- Venue
- Journal of Nephrology
- Publisher
- SAGE Publications
- Published
- 2012-05-23
- Volume
- 26
- Issue
- 1
- Pages
- 55-60
- ISSN
- 1121-8428 (ISSN-L)
- OpenAlex
- W1983905964
- Cited by
- 51
- References
- 5
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.